Search

Your search keyword '"Trojaniello, C"' showing total 72 results

Search Constraints

Start Over You searched for: Author "Trojaniello, C" Remove constraint Author: "Trojaniello, C"
72 results on '"Trojaniello, C"'

Search Results

2. Gene Signatures predict immune-related skin adverse events in melanoma patients

4. Neoadjuvant plus adjuvant combined or sequenced vemurafenib, cobimetinib and atezolizumab in patients with high-risk, resectable BRAF-mutated and wild-type melanoma: NEO-TIM, a phase II randomized non-comparative study

5. Correction to: Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial (Journal of Translational Medicine, (2020), 18, 1, (405), 10.1186/s12967-020-02573-9)

6. Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial

7. Corrigendum: “Real world data of cemiplimab in locally advanced and metastatic cutaneous squamous cell carcinoma” (European Journal of Cancer (2021) 157 (250–258), (S0959804921005360), (10.1016/j.ejca.2021.08.018))

8. Corrigendum to 'Real world data of cemiplimab in locally advanced and metastatic cutaneous squamous cell carcinoma' [Eur J Canc 157 (2021) 250-258]

9. 1042P Anti-PD1 (PD1) monotherapy or in combination with ipilimumab (IPI) after BRAF/MEK inhibitors (BRAF/MEKi) in BRAF mutant metastatic melanoma (MM) patients (pts)

10. 1047P Efficacy of checkpoint inhibitors (CPIs) in acral melanoma (AM)

13. Correction to: Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial (Journal of Translational Medicine, (2020), 18, 1, (405), 10.1186/s12967-020-02573-9)

14. Melanoma recurrence patterns and management after adjuvant targeted therapy: a multicentre analysis.

15. The role of local therapy in the treatment of solitary melanoma progression on immune checkpoint inhibition: A multicentre retrospective analysis

16. Real world data of cemiplimab in locally advanced and metastatic cutaneous squamous cell carcinoma

18. 1080MO The value of local therapy in treatment of solitary melanoma progression upon immune checkpoint inhibition

19. P26 HOMOCYSTEINE IN INFECTIVE ENDOCARDITIS

20. P36 PRELIMINARY STUDY ON THE DIAGNOSTIC VALUE OF PET–CT SCAN IN CARDIOVASCULAR INFECTIONS

21. P31 PROSPECTIVE STUDY OF CARDIAC IMPLANTABLE ELECTRONIC DEVICE INFECTIVE ENDOCARDITIS

22. The value of local therapy in treatment of solitary melanoma progression upon immune checkpoint inhibition

23. Nature and management of melanoma recurrences following adjuvant anti-PD-1 based therapy.

24. Impact of cemiplimab treatment duration on clinical outcomes in advanced cutaneous squamous cell carcinoma.

25. The features and management of acquired resistance to PD1-based therapy in metastatic melanoma.

26. Discontinuation of anti-PD1 in advanced melanoma: an observational retrospective study from the Italian Melanoma Intergroup.

27. Sequencing Targeted and Immune Therapy in BRAF-Mutant Melanoma: Lessons Learned.

28. Durability of response to immune checkpoint inhibitors in metastatic Merkel cell carcinoma after treatment cessation.

29. IL-6 as new prognostic factor in patients with advanced cutaneous squamous cell carcinoma treated with cemiplimab.

30. Neoadjuvant plus adjuvant combined or sequenced vemurafenib, cobimetinib and atezolizumab in patients with high-risk, resectable BRAF-mutated and wild-type melanoma: NEO-TIM, a phase II randomized non-comparative study.

31. Nivolumab serum concentration in metastatic melanoma patients could be related to outcome and enhanced immune activity: a gene profiling retrospective analysis.

32. Corrigendum to "Real world data of cemiplimab in locally advanced and metastatic cutaneous squamous cell carcinoma" [Eur J Canc 157 (2021) 250-258].

33. CTLA-4 Blockade Resistance after Relatlimab and Nivolumab.

34. Anorectal and Genital Mucosal Melanoma: Diagnostic Challenges, Current Knowledge and Therapeutic Opportunities of Rare Melanomas.

35. Real world data of cemiplimab in locally advanced and metastatic cutaneous squamous cell carcinoma.

36. Ipilimumab versus ipilimumab plus anti-PD-1 for metastatic melanoma - Authors' reply.

37. The role of local therapy in the treatment of solitary melanoma progression on immune checkpoint inhibition: A multicentre retrospective analysis.

38. Therapeutic Advancements Across Clinical Stages in Melanoma, With a Focus on Targeted Immunotherapy.

39. Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study.

40. Ipilimumab and Stereotactic Radiosurgery with CyberKnife ® System in Melanoma Brain Metastases: A Retrospective Monoinstitutional Experience.

41. Triplet combination of BRAF, MEK and PD-1/PD-L1 blockade in melanoma: the more the better?

42. Melanoma recurrence patterns and management after adjuvant targeted therapy: a multicentre analysis.

43. May the analysis of 1918 influenza pandemic give hints to imagine the possible magnitude of Corona Virus Disease-2019 (COVID-19)?

44. Outcomes and biomarker analyses among patients with COVID-19 treated with interleukin 6 (IL-6) receptor antagonist sarilumab at a single institution in Italy.

46. Melanoma immunotherapy: strategies to overcome pharmacological resistance.

47. Nivolumab for the treatment of small cell lung cancer.

48. Immunotherapy in metastatic melanoma: a novel scenario of new toxicities and their management.

49. The Role of BRAF-Targeted Therapy for Advanced Melanoma in the Immunotherapy Era.

50. Encorafenib in combination with binimetinib for unresectable or metastatic melanoma with BRAF mutations.

Catalog

Books, media, physical & digital resources